This is an international site for AFINITOR® (everolimus) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country

I am a healthcare professional outside of the US I am a US Resident I am a patient outside of the US

AFINITOR® (everolimus) Logo | AFINITOR.com
AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor now approved in the EU!
Afinitor International Website  |  For Healthcare Professionals Outside the U.S.  |  US Residents
Dosing & Administration

AFINITOR For Your Patients


Stay informed on the latest information, including news related to AFINITOR and other updates.

Register for Afinitor Updates
Afinitor Approved Countries

Learn About Prescribing AFINITOR®

In advanced renal cell carcinoma, after disease progression or after VEGF**-targeted therapy: AFINITOR — The once-daily, oral therapy

Simple dosing regimen is convenient for patients

  • AFINITOR is available in 10-mg or 5-mg once-daily tablets
  • Once daily oral administration allows for continuous mTOR inhibition

AFINITOR is easy to administer

  • Dosage is the same regardless of age, gender, body weight or renal function
  • No premedication is required
  • Take once daily at the same time every day, consistently either with or without food

Flexible dosing strategies

  • Dose may be reduced to 5 mg daily or interrupted as appropriate to manage severe and/or intolerable adverse reactions
Prescribing AFINITOR® (everolimus) Tablets

Packaging shown may vary from the AFINITOR package available in your country

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

**VEGF: vascular endothelial growth factor